Masimo (NASDAQ:MASI) Price Target Increased to $148.00 by Analysts at Stifel Nicolaus

Masimo (NASDAQ:MASI) had its price target raised by Stifel Nicolaus from $125.00 to $148.00 in a research note published on Monday morning, Benzinga reports. Stifel Nicolaus currently has a hold rating on the medical equipment provider’s stock.

A number of other analysts have also weighed in on the company. Needham & Company LLC lowered Masimo from a buy rating to a hold rating in a research note on Wednesday, January 3rd. Wells Fargo & Company upgraded Masimo from an equal weight rating to an overweight rating and raised their target price for the company from $117.00 to $160.00 in a research note on Monday. Jefferies Financial Group restated a hold rating and issued a $121.00 target price (up from $107.00) on shares of Masimo in a research note on Tuesday, January 30th. BTIG Research lifted their price objective on Masimo from $145.00 to $166.00 and gave the stock a buy rating in a research report on Monday. Finally, StockNews.com lowered Masimo from a hold rating to a sell rating in a research report on Thursday, March 21st. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Masimo has an average rating of Hold and a consensus price target of $134.29.

Masimo Stock Up 1.6 %

Shares of NASDAQ MASI opened at $146.85 on Monday. The stock has a market cap of $7.77 billion, a PE ratio of 97.25 and a beta of 0.95. The business has a fifty day moving average of $132.25 and a two-hundred day moving average of $109.52. Masimo has a 52-week low of $75.22 and a 52-week high of $198.00. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.22 and a current ratio of 2.18.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.43. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The company had revenue of $548.90 million during the quarter, compared to analysts’ expectations of $545.69 million. During the same period last year, the business earned $1.32 earnings per share. The business’s revenue was down 11.0% on a year-over-year basis. As a group, equities research analysts expect that Masimo will post 3.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Masimo

Several institutional investors have recently modified their holdings of MASI. Massmutual Trust Co. FSB ADV grew its position in shares of Masimo by 140.6% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares during the period. Byrne Asset Management LLC acquired a new position in shares of Masimo during the 4th quarter worth about $28,000. DHJJ Financial Advisors Ltd. acquired a new position in shares of Masimo during the 3rd quarter worth about $32,000. NBC Securities Inc. acquired a new position in shares of Masimo during the 3rd quarter worth about $34,000. Finally, EverSource Wealth Advisors LLC grew its position in shares of Masimo by 851.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 295 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 264 shares during the period. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.